Maricar Malinis

Maricar Malinis, MD, joined the Section of Infectious Diseases faculty in 2013. She is an Associate Professor of Medicine with a secondary appointment in the Department of Surgery (Transplant) and the Medical Director of the Transplant and Oncology Infectious Diseases Program.

She obtained her bachelor's degree in Chemistry at the University of the Philippines Diliman and her medical degree at the University of the Philippines College of Medicine. She came to the United States for post-graduate training. She completed her internal medicine residency at Seton Hall Graduate Medical Education. Afterward, she did fellowship training in Geriatric Medicine at the University of Michigan, Infectious Diseases at the University of Louisville, and Transplant Infectious Diseases at the Cleveland Clinic Foundation.

She is an active member of the American Society of Transplantation (AST), the Transplantation Society, and the IDSA. She was the inaugural chair of the AST IDCOP Older Adult Working Group (2019-2021). In addition, she is currently serving her term as the member-at-large of the AST ID COP and the councilor of the Transplant Infectious Diseases Section of The Transplantation Society. She completed her 4-year term as an IDSA Clinical Affairs Committee member in 2021. She is an inaugural IDSA Digital Advisory Group member, served as vice-chair between 2020-2021, and chair 2021-2023. She also served as a Member-at-large of the Organ Procurement Transplant Network Ad hoc Disease Transmission Advisory Committee between 2017-2020. She is a Member-at-large of the OPTN/UNOS Member and Professional Standards Committee (2023-2025).

She is the co-director of the Transplant Infectious Disease Clinical Track and the Joint Adult and Pediatric Transplant Infectious Diseases Conference. Her research focuses on clinical outcomes of transplantation in people living with HIV and older adults. She is the primary investigator of the HIV Organ Policy Equity (HOPE) Act clinical trial at Yale and several multi-center clinical trials of novel anti-viral agents for immunocompromised hosts. Lastly, she led projects on patient safety and quality improvement of care in transplant candidates and recipients, such as optimizing vaccination uptake in this population.